Valuation: Allogene Therapeutics, Inc.

Market Cap 594M 515M 487M 441M 827M 57B 833M 5.81B 2.23B 28.9B 2.23B 2.18B 92.18B P/E 2026 *
-2.85x
P/E 2027 * -2.68x
Enterprise Value 398M 345M 326M 295M 554M 38.15B 558M 3.89B 1.5B 19.34B 1.49B 1.46B 61.69B EV / Sales 2026 *
117x
EV / Sales 2027 * 36.7x
Free-Float
83.55%
Yield 2026 *
-
Yield 2027 * -
Sep. 09 Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM
Sep. 02 Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026 CI
Sep. 02 Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Executive Vice President and Principal Financial Officer, Effective November 6, 2026 CI
Sep. 02 Allogene Therapeutics CFO Geoffrey Parker to Retire MT
Aug. 13 Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says MT
Aug. 12 Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
Aug. 12 Allogene Therapeutics Q2 Loss Narrows MT
Aug. 12 Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss MT
Aug. 12 Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 12 Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL CI
Jul. 29 Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations MT
Jul. 29 Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma CI
Jul. 15 Allogene Therapeutics Publishes Phase 1 Results of Allo-316 in Journal of Clinical Oncology CI
1 day-3.37%
1 week-7.53%
Current month-14.00%
1 month-16.10%
3 months-11.34%
6 months-28.33%
Current year+25.55%
1 week 1.7
Extreme 1.695
1.84
1 month 1.7
Extreme 1.695
2.23
Current year 1.31
Extreme 1.31
4.46
1 year 1.04
Extreme 1.04
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
27.86
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 2026-06-30
Director of Finance/CFO 61 2023-10-15
Chief Tech/Sci/R&D Officer 49 2025-02-27
Director TitleAgeSince
Chairman 76 2017-10-31
Director/Board Member 66 2018-05-31
Director/Board Member 49 2017-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Sell

Compliance Officer

-29,697 0.0086%
7/1/26 Free

Chief Executive Officer

610,720 0.1769%
6/18/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-3.37%-7.53%+49.57%-55.78% 615M
-1.38%+0.20%+46.42%+96.33% 70.24B
-1.04%-0.81%+34.61%+75.16% 62.63B
-4.29%-3.98%-16.22%+350.66% 27.36B
+1.58%+2.48%+29.13%+14.79% 25.71B
-2.20%-2.00%-1.22%-14.48% 24.83B
+1.61%-0.69%+20.85%-19.42% 19.52B
+1.26%-14.23%+170.04%+298.75% 15.51B
-5.54%+0.69%-8.13%+830.48% 14.69B
-0.69%-4.37%-9.98%+454.22% 14.66B
Average -1.38%-2.73%+31.51%+203.07% 27.58B
Weighted average by Cap. -1.20%-1.33%+30.86%+160.18%

Financials

2026 *2027 *
Net sales 3.4M 2.95M 2.78M 2.52M 4.73M 326M 4.77M 33.23M 12.79M 165M 12.77M 12.49M 527M 12.09M 10.47M 9.9M 8.96M 16.82M 1.16B 16.95M 118M 45.45M 588M 45.4M 44.39M 1.87B
Net income -185M -160M -152M -137M -258M -17.76B -260M -1.81B -696M -9.01B -695M -680M -28.72B -220M -190M -180M -163M -306M -21.09B -308M -2.15B -827M -10.69B -826M -807M -34.1B
Net Debt -197M -170M -161M -146M -274M -18.85B -276M -1.92B -739M -9.56B -738M -722M -30.48B -150M -130M -123M -111M -209M -14.41B -211M -1.47B -565M -7.3B -564M -552M -23.29B
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
26-09-15 $1.720 -3.37% 3,138,543
26-09-14 $1.780 0.00% 7,750,773
26-09-11 $1.780 +1.14% 3,894,350
26-09-10 $1.760 +1.73% 5,401,051
26-09-09 $1.730 -6.99% 7,284,015
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1.720USD
Average target price
9.000USD
Spread / Average Target
+423.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALLO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!